Peldesine

Peldesine (BCX 34) is a potent, competitive, reversible and orally active purine nucleoside phosphorylase (PNP) inhibitor with IC50s of 36 nM, 5 nM, and 32 nM for human, rat, and mouse red blood cell (RBC) PNP, respectively. Peldesine is also a T-cell proliferation inhibitor with an IC50 of 800 nM. Peldesine has the potential for cutaneous T-cell lymphoma, psoriasis and HIV infection research[1][2][3][4].

Product Specifications

CAS Number

[133432-71-0]

Product Name Alternative

BCX 34

UNSPSC

12352005

Target

HIV; Nucleoside Antimetabolite/Analog

Type

Reference compound

Related Pathways

Anti-infection; Cell Cycle/DNA Damage

Applications

COVID-19-anti-virus

Field of Research

Cancer; Infection; Inflammation/Immunology

Assay Protocol

https://www.medchemexpress.com/peldesine.html

Concentration

10mM

Purity

98.06

Smiles

O=C1C(NC=C2CC3=CC=CN=C3)=C2N=C(N)N1

Molecular Formula

C12H11N5O

Molecular Weight

241.25

References & Citations

[1]Wada Y, et al. BCX-34: a novel T-cell selective immunosuppressant: purine nucleoside phosphorylase (PNP) inhibitor. Artif Organs. 1996 Aug;20 (8) :849-52.|[2]Duvic M, et al. A phase III, randomized, double-blind, placebo-controlled study of peldesine (BCX-34) cream as topical therapy for cutaneous T-cell lymphoma. J Am Acad Dermatol. 2001 Jun;44 (6) :940-7.|[3]Bantia S, et al. In vivo and in vitro pharmacologic activity of the purine nucleoside phosphorylase inhibitor BCX-34: the role of GTP and dGTP. Immunopharmacology. 1996 Oct;35 (1) :53-63.|[4]New AIDS study suppresses T cells to stop viral growth. AIDS Alert. 1997 Jul;12 (7) :77-8.